- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02747017
Observational Study of C. Diff in Post-Transplant Patients (CDIFF)
October 30, 2019 updated by: University of Minnesota
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
The primary objective of this observational study is to estimate the 90-day response rates to treatment for a first episode of C. difficile infections (CDI) in adult transplant recipients.
Study Overview
Status
Completed
Conditions
Detailed Description
The primary objective of this observational study is to estimate the 90-day response rates to treatment for a first episode of C. difficile infections (CDI) in adult transplant recipients.
This includes treatment success, recurrence, and complications in a prospectively followed cohort of solid organ and hematopoietic stem cell transplant patients.
Patients who develop CDI within 2 years after transplantation will be enrolled and followed prospectively for 90 days after enrollment.
Specimens of stool and serum collected within 48 hours of initiation of treatment will be stored locally for future epidemiologic studies to examine the immunologic and microbiologic risk factors for relapse and treatment failure, as well as complications of CDI in the transplant population.
Response rates will be classified by organ type, hematopoietic stem cell transplant typ, treatment regimen, and immunosuppressive regimen.
Study Type
Observational
Enrollment (Actual)
132
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Buenos Aires, Argentina, C1181ACH
- Hospital Italiano de Buenos Aires
-
-
-
-
-
Copenhagen, Denmark, 2100
- CHIP, Department of Infectious Diseases, Section 2100
-
-
-
-
-
Cologne, Germany
- Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV
-
-
-
-
-
Barcelona, Spain
- Hospital Clinic De Barcelona
-
Madrid, Spain
- Hospital Universitario Doce de Octubre
-
-
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adults with a first episode of CDI within 2 years post solid-organ or stem-cell transplant.
Description
Inclusion Criteria:
- Age ≥ 18 years
- Signed informed consent
- Transplant recipient (solid organ, stem cells, or bone marrow) within past 2 years
- Currently diagnosed with first CDI after transplant, defined by (1) presence of diarrhea (at least 3 loose stools within a 24-hour period), AND (2) detection of C. difficile cytotoxin in stools by cytotoxin assay, or toxigenic culture, or polymerase chain reaction (PCR) testing for toxin, or enzyme immunoassay, or endoscopic presence of pseudomembranes with the detection of C. difficile in tissue biopsies
Exclusion Criteria:
- Previous episode of CDI anytime after transplant
- Current treatment for another infectious cause of diarrhea (bacterial, viral, or parasitic) at the time of the current CDI diagnosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
CDI patients
Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to antibiotic treatment for CDI: clinical cure
Time Frame: 90 days
|
The planned first course of CDI treatment was completed with resolution of symptoms or less than 3 loose stools per day for at least two consecutive days maintained until end of treatment and two days after treatment course ended.
|
90 days
|
Response to antibiotic treatment for CDI: sustained clinical cure
Time Frame: 90 days
|
Clinical cure achieved and maintained for 40 days post treatment initiation without recurrences, complications, ICU with CDI, or death as defined below
|
90 days
|
Response to antibiotic treatment for CDI: global cure
Time Frame: 90 days
|
Clinical cure achieved and maintained for 90 days post treatment initiation without recurrences, complications, including ICU with CDI, or death as defined below.
|
90 days
|
Response to antibiotic treatment for CDI: relapse
Time Frame: 90 days
|
A new episode of CDI after clinical cure and within 4 weeks after treatment initiation.
|
90 days
|
Response to antibiotic treatment for CDI: reinfection
Time Frame: 90 days
|
A new episode of CDI after clinical cure and beyond 4 weeks after treatment initiation
|
90 days
|
Response to antibiotic treatment for CDI: complications
Time Frame: 90 days
|
The study will collect the incidence of specific complications as assessed by the site investigator: perforation of the colon; development of toxic megacolon; need for abdominal surgery related to CDI; transfer to the ICU with CDI; death from CDI-related cause.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describe patients who are successfully treatment for CDI
Time Frame: 90 days
|
Patients will be described by demographics (age, race, sex), type of transplant received, specific treatment for CDI, and the strain of C. difficile with which they were infected.
|
90 days
|
Describe differences in antibiotic regimens and other CDI treatments across geographic regions (US, Europe, South America)
Time Frame: 90 days
|
90 days
|
|
All-cause mortality
Time Frame: 90 days
|
90 days
|
|
Response to treatment for CDI (as defined above) by treatment regimen
Time Frame: 90 days
|
90 days
|
|
Response to treatment for CDI (as defined above) by type of transplant (solid organ vs. hematopoietic/stem cell)
Time Frame: 90 days
|
90 days
|
|
Assay differences across sites
Time Frame: 90 days
|
Describe assays used to detect C. difficile organisms and toxin in stool by site at which participants are enrolled.
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Jean-Michel Molina, MD, Hôpital Saint-Louis, Service de Maladies Infectieuses
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 22, 2016
Primary Completion (Actual)
October 30, 2018
Study Completion (Actual)
October 30, 2018
Study Registration Dates
First Submitted
April 12, 2016
First Submitted That Met QC Criteria
April 18, 2016
First Posted (Estimate)
April 21, 2016
Study Record Updates
Last Update Posted (Actual)
November 1, 2019
Last Update Submitted That Met QC Criteria
October 30, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 1605M87565
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Difficile
-
DeinoveRecruitingClostridium Difficile (C. Difficile)United States, Canada
-
Vedanta Biosciences, Inc.CompletedClostridium Difficile Infection | Clostridium Difficile Infection Recurrence | Clostridium Difficile | CDI | Clostridioides Difficile Infection | Clostridioides Difficile | Clostridioides Difficile Infection RecurrenceUnited States, Canada
-
Hamilton Health Sciences CorporationRecruitingClostridium Difficile Diarrhea | Clostridium Difficile ColonizationCanada
-
Vedanta Biosciences, Inc.Not yet recruitingClostridium Difficile Infection Recurrence | Recurrent Clostridium Difficile Infection | Clostridium Difficile | Diarrhea Infectious | CDI | Clostridium Difficile Infections | Clostridioides Difficile Infection | C.Difficile Diarrhea | Clostridioides Difficile Infection Recurrence | C. Diff Infection
-
University of AlbertaTerminatedClostridium DifficileCanada
-
McMaster UniversitySt. Joseph's Healthcare HamiltonTerminated
-
Astellas Pharma Europe Ltd.Merck Sharp & Dohme LLCCompletedClostridium DifficileGreece, Spain, Russian Federation, Denmark, Austria, Belgium, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Poland, Portugal, Romania, Slovenia, Sweden, Switzerland, Turkey, United Kingdom
-
Microbiome Health Research InstituteBrown University; Tufts Medical Center; Indiana University; Edward HospitalTerminatedClostridium DifficileUnited States
-
Seres Therapeutics, Inc.Syneos HealthCompletedClostridium DifficileUnited States
-
University of Wisconsin, MadisonAgency for Healthcare Research and Quality (AHRQ)Enrolling by invitationClostridium Difficile Infection | Clostridium Difficile | C Difficile ColitisUnited States